2024 Immune Thrombocytopenia American Society of Hematology (ITP ASH)
Description
The ITP ASH 2024 grant initiative, offered by SANOFI, is designed to identify and fund projects that aim to close significant healthcare gaps related to the treatment and management of Immune Thrombocytopenia (ITP). ITP is a rare blood disorder characterized by a significantly reduced platelet count, leading to a heightened risk of bleeding and serious health complications such as thrombosis and hematologic malignancy. The chronic nature of ITP often results in a diminished quality of life for patients, manifesting in anxiety, fatigue, and depression due to ongoing concerns about bleeding risks and ineffective current therapies.
SANOFI is particularly interested in supporting educational and therapeutic strategies that promise to enhance the clinical handling of ITP, focusing on innovative treatment methodologies and educational activities that can lead to improved patient outcomes. Proposals are invited for projects including, but not limited to, live symposiums at medical conferences, enduring materials for broader educational reach, and both accredited and non-accredited Independent Medical Education (IME) activities. A budget cap of $425,000 is set for the grant, with a strong preference for proposals that incorporate evidence-based approaches and demonstrate potential to address knowledge gaps among healthcare providers, thus improving treatment practices.